Summit Therapeutics Inc.

Oncology biotech developing ivonescimab, a PD-1/VEGF bispecific, across multiple global Phase 3 lung and colorectal cancer programs.

Back to company catalog

Oncology · PD-1/VEGF bispecific antibody · BLA under FDA review + Phase 3

Compare report options